Durma, A.D.; Saracyn, M.; Kołodziej, M.; Jóźwik-Plebanek, K.; Brodowska-Kania, D.; Dmochowska, B.; Mróz, A.; Kos-Kudła, B.; Kamiński, G.
Adverse Events of Radioligand Therapy in Patients with Progressive Neuroendocrine Neoplasms: The Biggest Eastern European Prospective Study. Cancers 2024, 16, 3509.
https://doi.org/10.3390/cancers16203509
AMA Style
Durma AD, Saracyn M, Kołodziej M, Jóźwik-Plebanek K, Brodowska-Kania D, Dmochowska B, Mróz A, Kos-Kudła B, Kamiński G.
Adverse Events of Radioligand Therapy in Patients with Progressive Neuroendocrine Neoplasms: The Biggest Eastern European Prospective Study. Cancers. 2024; 16(20):3509.
https://doi.org/10.3390/cancers16203509
Chicago/Turabian Style
Durma, Adam Daniel, Marek Saracyn, Maciej Kołodziej, Katarzyna Jóźwik-Plebanek, Dorota Brodowska-Kania, Beata Dmochowska, Adrianna Mróz, Beata Kos-Kudła, and Grzegorz Kamiński.
2024. "Adverse Events of Radioligand Therapy in Patients with Progressive Neuroendocrine Neoplasms: The Biggest Eastern European Prospective Study" Cancers 16, no. 20: 3509.
https://doi.org/10.3390/cancers16203509
APA Style
Durma, A. D., Saracyn, M., Kołodziej, M., Jóźwik-Plebanek, K., Brodowska-Kania, D., Dmochowska, B., Mróz, A., Kos-Kudła, B., & Kamiński, G.
(2024). Adverse Events of Radioligand Therapy in Patients with Progressive Neuroendocrine Neoplasms: The Biggest Eastern European Prospective Study. Cancers, 16(20), 3509.
https://doi.org/10.3390/cancers16203509
